Understanding Erectile Dysfunction and the Need for Regenerative Approaches

Erectile Dysfunction is a widespread condition affecting approximately 340 million men worldwide, with prostate cancer being the most common cause. The incidence of ED is on the rise due to the increasing prevalence of age, prostate cancer, and diabetes. Current treatment options, including medication, provide only symptomatic relief and have significant side effects. Moreover, these treatments do not restore the original organ function, resulting in a lifelong need for medication. As a result, there is an unmet clinical need for more effective and long-lasting treatment options.

Regenerative approaches, such as Blue Cell therapy, hold the promise of reducing the burden of chronic diseases on public healthcare systems and improving the quality of life for patients suffering from ED. By developing immunomodulatory and regenerative cell therapies, we can create novel treatment modalities that address the underlying cause of the disease, rather than just treating the symptoms. These therapies represent a significant breakthrough in the treatment of ED and have the potential to improve the lives of millions of men worldwide.


Blue Cells are a type of progenitor cells that can help treat ED. They do this by inhibiting inflammation and promoting regeneration, repairing endothelial cells, vascular smooth muscle cells, and neurons. ED occurs when the penile nerves suffer from a type of nerve damage, which leads to reduced release of nitric oxide and inability to achieve an erection. Lack of nocturnal erections also causes fibrosis of penile tissue and apoptosis of endothelial cells in the cavernous sinuses, resulting in permanent ED.

In a previous phase 1 study, 8 out of 11 men who received ADRC treatment regained erectile function completely, even though they had ED for one year or more after a prostatectomy and had no effect from PDE-5 inhibitors like Viagra. Blue Cells can restore penile erectile function, and these cells can now be cultured so the treatment can be available to patients worldwide.